One of the most critical topics to address in health care today is the mental health and well-being of physicians and other ...

Eli Lilly will be licensing Alchemab Therapeutics’ preclinical programme for amyotrophic lateral sclerosis (ALS) and other ...

Johnson & Johnson (J&J) has shared positive long-term results from a phase 3 trial of its dual-acting IL-23 inhibitor Tremfya ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bavarian Nordic’s Vimkunya (recombinant, adsorbed ...

The relationship between patient advocacy groups (PAGs) and pharmaceutical companies face challenges that if addressed could ...

AstraZeneca (AZ) has announced that its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) has been approved ...

Alnylam Pharmaceuticals’ RNAi therapeutic vutrisiran has been recommended by the European Medicines Agency’s human medicines ...

Bristol Myers Squibb (BMS) has announced that an injectable version of its cancer immunotherapy Opdivo (nivolumab) has been ...

What impact can we expect from the abolition of NHS England (NHSE) and changes at the Department of Health and Social Care ...

Johnson & Johnson (J&J) has received approval from the US Food and Drug Administration for its FcRn blocker Imaavy ...

The once-a-day drug has been recommended for patients with a history of previous medical or surgical treatment ...

AZ’s triple-combination therapy is already approved under the brand names Breztri Aerosphere and Trixeo Aerosphere to treat ...